Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

The tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) have shown anti-tumor activity in the treatment of non-small cell lung cancer (NSCLC). Dramatic and durable responses have occurred in NSCLC tumors with mutations in the tyrosine kinase domain of the epidermal growth factor re...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ji, Hongbin, Zhao, Xiaojun, Yuza, Yuki, Shimamura, Takeshi, Li, Danan, Protopopov, Alexei, Jung, Boonim L., McNamara, Kate, Xia, Huili, Glatt, Karen A., Thomas, Roman K., Sasaki, Hidefumi, Horner, James W., Eck, Michael, Mitchell, Albert, Sun, Yangping, Al-Hashem, Ruqayyah, Bronson, Roderick T., Rabindran, Sridhar K., Discafani, Carolyn M., Maher, Elizabeth, Shapiro, Geoffrey I., Meyerson, Matthew, Wong, Kwok-Kin
Materialtyp: Artigo
Språk:Inglês
Publicerad: National Academy of Sciences 2006
Ämnen:
Biological Sciences
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC1456806/
https://ncbi.nlm.nih.gov/pubmed/16672372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0510284103
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk